Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Pain ; 7(10): 735-46, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17018334

RESUMEN

UNLABELLED: Vanilloid receptor subunit 1 (TRPV1) is an integrator of physical and chemical stimuli in the peripheral nervous system. This receptor plays a key role in the pathophysiology of inflammatory pain. Thus, the identification of receptor antagonists with analgesic and anti-inflammatory activity in vivo is an important goal of current neuropharmacology. Here, we report that [L-arginyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl) glycinamide (H-Arg-15-15C) is a channel blocker that abrogates capsaicin and pH-evoked TRPV1 channel activity with submicromolar activity. Compound H-Arg-15-15C preferentially inhibits TRPV1, showing marginal block of other neuronal receptors. Compound H-Arg-15-15C acts as a noncompetitive capsaicin antagonist with modest voltage-dependent blockade activity. The compound inhibited capsaicin-evoked nerve activity in afferent fibers without affecting mechanically activated activity. Notably, administration of compound H-Arg-15-15C prevented the irritant activity of a local administration of capsaicin and formalin and reversed the thermal hyperalgesia evoked by injection of complete Freund's adjuvant. Furthermore, it attenuated carrageenan-induced paw inflammation. Compound H-Arg-15-15C specifically decreased inflammatory conditions without affecting normal nociception. Taken together, these findings demonstrate that compound H-Arg-15-15C is a channel blocker of TRPV1 with analgesic and anti-inflammatory activity in vivo at clinically useful doses and substantiate the tenet that TRPV1 plays an important role in the etiology of chronic inflammatory pain. PERSPECTIVE: This study reports the design of a potent TRPV1 noncompetitive antagonist that exhibits anti-inflammatory and analgesic activity in preclinical models of acute and chronic pain. This compound is a lead for analgesic drug development.


Asunto(s)
Analgésicos/farmacología , Antiinflamatorios/farmacología , Arginina/análogos & derivados , Glicina/análogos & derivados , Canales Iónicos/antagonistas & inhibidores , Nociceptores/efectos de los fármacos , Dolor/tratamiento farmacológico , Canales Catiónicos TRPV/antagonistas & inhibidores , Analgésicos/síntesis química , Analgésicos/química , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Arginina/síntesis química , Arginina/química , Arginina/farmacología , Células COS , Capsaicina/antagonistas & inhibidores , Chlorocebus aethiops , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Femenino , Glicina/síntesis química , Glicina/química , Glicina/farmacología , Inflamación/tratamiento farmacológico , Inflamación/fisiopatología , Canales Iónicos/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR , Nociceptores/metabolismo , Nociceptores/fisiopatología , Oocitos , Dolor/fisiopatología , Técnicas de Placa-Clamp , Ratas , Ratas Wistar , Células Receptoras Sensoriales/efectos de los fármacos , Células Receptoras Sensoriales/fisiología , Canales Catiónicos TRPV/metabolismo , Xenopus
2.
J Neurochem ; 98(2): 430-45, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16805837

RESUMEN

Guanosine (Guo) is an endogenous neuroprotective molecule of the CNS, which has various acute and long-term effects on both neurones and astroglial cells. Whether Guo also modulates the activity/expression of ion channels involved in homeostatic control of extracellular potassium by the astrocytic syncytium is still unknown. Here we provide electrophysiological evidence that chronic exposure (48 h) to Guo (500 microm) promotes the functional expression of an inward rectifier K+ (Kir) conductance in primary cultured rat cortical astrocytes. Molecular screening indicated that Guo promotes the up-regulation of the Kir4.1 channel, the major component of the Kir current in astroglia in vivo. Furthermore, the properties of astrocytic Kir current overlapped those of the recombinant Kir4.1 channel expressed in a heterologous system, strongly suggesting that the Guo-induced Kir conductance is mainly gated by Kir4.1. In contrast, the expression levels of two other Kir channel proteins were either unchanged (Kir2.1) or decreased (Kir5.1). Finally, we showed that inhibition of translational process, but not depression of transcription, prevents the Guo-induced up-regulation of Kir4.1, indicating that this nucleoside acts through de novo protein synthesis. Because accumulating data indicate that down-regulation of astroglial Kir current contributes to the pathogenesis of neurodegenerative diseases associated with dysregulation of extracellular K+ homeostasis, these results support the notion that Guo might be a molecule of therapeutic interest for counteracting the detrimental effect of K+-buffering impairment of the astroglial syncytium that occurs in pathological conditions.


Asunto(s)
Astrocitos/metabolismo , Corteza Cerebral/metabolismo , Guanosina/farmacología , Canales de Potasio de Rectificación Interna/fisiología , Animales , Astrocitos/efectos de los fármacos , Western Blotting , Células COS , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Chlorocebus aethiops , ADN Complementario/biosíntesis , ADN Complementario/genética , Electrofisiología , Homeostasis , Inmunoprecipitación , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Fármacos Neuroprotectores , Técnicas de Placa-Clamp , Canales de Potasio de Rectificación Interna/biosíntesis , Ratas , Transfección , Regulación hacia Arriba/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA